摘要
目的研究特利加压素对肝硬化难治性腹水的临床疗效。方法选取我院2012年3月至2014年8月62例肝硬化难治性腹水患者为研究对象，将患者随机分为观察组和对照组，每组31例。观察组采用特利加压素治疗，对照组采用保肝等常规治疗。比较两组的临床疗效、体征变化、门静脉内径、脾静脉内径、腹水深度、不良反应。结果观察组的治疗总有效率为83．9％，显著高于对照组的61．3％（P〈0．05）。观察组治疗后的24h尿量为（1148．76±19．35）ml，显著高于对照组的（1069．48±17．51）ml（P〈0．05）；观察组治疗后的体重、腹围、门静脉内径、脾静脉内径、腹水深度分别为（61．76±4．16）妇、（90．32±3．58）cm、（11．27±1．35）mm、（7．58±0．96）mm、（41．19±17．22）mm，显著低于对照组的（65．35±6．71）kg、（98．16±3．27）cm、（12．48±0．69）mm、（9．23±1．18）mm、（53．86±16．63）mm（P〈0．05）。观察组在治疗过程中发生轻微腹痛1例，大便次数增多2例，以上不良症状较轻，均自行缓解。结论特利加压素治疗肝硬化难治性腹水可以有效减小门、脾静脉内径，减少腹腔积水，改善患者的肝功能，疗效显著，安全可靠，值得临床应用和推广。
Objective To study the clinical curative effect of terlipressin in patients with cirrhosis and refractory ascites. Methods 62 patients with cirrhosis and refractory ascites in our hospital from March 2012 to August 2014 were selected as the object of study, randomly divided into observation group and control group, 31 cases in each group. Observation group was treated with terlipressin, control group received liver protection and other conventional treatment. Compared clinical curative effect, changes of vital signs, portal vein diameter, spleen vein diameter, depth of ascites, adverse reactions of two groups. Results The total effective rate of observation group was 83.9%, significantly higher than 61.3% of control group （P〈0.05）. After treatment, 24 h urine volume of observation group was （1148.76±19.35）ml, significantly higher than （1069.48±17.51）ml of control group （P〈0.05）. After treatment, body weight, abdominal circumference, portal vein diameter, spleen vein diameter, depth of ascites of observation group were （61.76±4.16）kg, （90.32±3.58）cm, （11.27±1.35）mm, （7.58±0.96）mm, （4 h 19± 17.22）mm, significantly lower than （65.35±6.71）kg, （98.16±3.27）cm, （ 12.48±0.69）mm, （9.23±1.18）mm, （53.86±16.63）mm of control group （P〈0.05）. There were 1 case of slight abdominal pain, 2 cases of increased stool frequency in observation group during the treatment, above adverse symptoms were lighter, all alleviated by oneself. Conclusion Terlipressin in the treatment of liver cirrhosis with refractory ascites can effectively reduce portal vein diameter, spleen vein diameter, ascites, improve the liver function of patients, with obvious curative effect, safe and reliable, worthy of clinical application and promotion.
出处
《国际医药卫生导报》
2017年第4期547-549,共3页
International Medicine and Health Guidance News
关键词
肝硬化
难治性腹水
特利加压素
Liver cirrhosis
Refractory ascites
Terlipressin
